Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSpruce Biosciences, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.48 | -$0.10 | -$0.29 |
| Q2 2024 | 1 | -$0.53 | -$0.11 | -$0.32 |
| Q3 2024 | 1 | -$0.39 | -$0.08 | -$0.24 |
| Q4 2024 | 3 | -$0.23 | -$0.19 | -$0.21 |
| Q1 2025 | 2 | -$0.20 | -$0.16 | -$0.18 |
| Q2 2025 | 1 | -$0.27 | -$0.06 | -$0.16 |
| Q3 2025 | 1 | -$0.25 | -$0.05 | -$0.15 |
| Q4 2025 | 1 | -$0.25 | -$0.05 | -$0.15 |
Spruce Biosciences, Inc. Earnings Date And Information
Spruce Biosciences, Inc. last posted its earnings results on Monday, November 11th, 2024. The company reported $-0.21 earnings per share for the quarter, topping analysts' consensus estimates of $-0.24 by $0.03. The company had revenue of 602,000 for the quarter and had revenue of 10.09 M for the year. Spruce Biosciences, Inc. has generated $-1 earnings per share over the last year ($-1.24 diluted earnings per share) and currently has a price-to-earnings ratio of -0.42. Spruce Biosciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
Spruce Biosciences, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 09/30/2024 | Q3 2024 | -$0.21 | $1.49 M | $602,000 | ||
| 08/12/2024 | Q2 2024 | -$0.33 | -$0.22 | 0.11 | $1.50 M | $1.61 M |
| 05/13/2024 | Q1 2024 | -$0.32 | -$0.28 | 0.04 | $2.00 M | |
| 03/18/2024 | Q4 2023 | -$0.24 | $2.89 M | |||
| 11/13/2023 | Q3 2023 | -$0.34 | -$0.30 | 0.04 | $2.25 M | $3.07 M |
| 08/14/2023 | Q2 2023 | -$0.37 | -$0.32 | 0.05 | $980,000 | $2.17 M |
| 05/15/2023 | Q1 2023 | -$0.42 | -$0.39 | 0.03 | $1.96 M | |
| 03/16/2023 | Q4 2022 | -$0.55 | -$0.43 | 0.12 | $0 | |
| 11/10/2022 | Q3 2022 | -$0.54 | -$0.48 | 0.06 | $0 | |
| 08/10/2022 | Q2 2022 | -$0.54 | -$0.51 | 0.03 | $0 | |
| 05/11/2022 | Q1 2022 | -$0.45 | -$0.50 | -0.05 | $0 | |
| 03/14/2022 | Q4 2021 | -$0.57 | -$0.39 | 0.18 | $0 | |
| 11/15/2021 | Q3 2021 | -$0.57 | -$0.49 | 0.08 | $0 | |
| 08/10/2021 | Q2 2021 | -$0.45 | -$0.50 | -0.05 | $0 | |
| 05/12/2021 | Q1 2021 | -$0.44 | -$0.42 | 0.02 | $0 | |
| 03/22/2021 | Q4 2020 | -$0.60 | -$0.39 | 0.21 | $0 | |
| 11/18/2020 | Q3 2020 | -$0.51 | -$0.43 | 0.08 | $0 | |
| 06/29/2020 | Q2 2020 | -$0.30 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.57 | $0 | |||
| 12/30/2019 | Q4 2019 | -$0.35 | $0 |
Spruce Biosciences, Inc. Earnings: FAQ's
When is Spruce Biosciences, Inc.'s earnings date?
Spruce Biosciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based off last year's report dates.
Did Spruce Biosciences, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Spruce Biosciences, Inc. (:SPRB) reported $-0.21 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.24 by $0.03.
How can I listen to Spruce Biosciences, Inc.'s earnings conference
call?
The conference call for Spruce Biosciences, Inc.'s latest earnings report can be listened to online.
How can I read Spruce Biosciences, Inc.'s conference call transcript?
The conference call transcript for Spruce Biosciences, Inc.'s latest earnings report can be read online.
How much revenue does Spruce Biosciences, Inc. generate each year?
Spruce Biosciences, Inc. (:SPRB) has a recorded annual revenue of $10.09 M.
How much profit does Spruce Biosciences, Inc. generate each year?
Spruce Biosciences, Inc. (:SPRB) has a recorded net income of $10.09 M. Spruce Biosciences, Inc. has generated $-1.24 earnings per share over the last four quarters.
What is Spruce Biosciences, Inc.'s price-to-earnings ratio?
Spruce Biosciences, Inc. (:SPRB) has a price-to-earnings ratio of -0.42 and price/earnings-to-growth ratio is -0.05.